

=> s neurotrophin# receptor#
L1 3567 NEUROTROPHIN# RECEPTOR#

=> s l1 (20a) activat###
L2 262 L1 (20A) ACTIVAT###

=> s l2 (40a) survival
L3 38 L2 (40A) SURVIVAL

=> duplicate remove
ENTER L# LIST OR (END):13
DUPLICATE PREFERENCE IS 'MEDLINE, BIOSIS, USPATFULL, PCTFULL'
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n
PROCESSING COMPLETED FOR L3
L4 34 DUPLICATE REMOVE L3 (4 DUPLICATES REMOVED)

=> d 1-34

L4 ANSWER 1 OF 34 USPATFULL on STN
AN 2004:196424 USPATFULL
TI Lectin compositions and methods for modulating an immune response to an antigen
IN Segal, Andrew H., Boston, MA, UNITED STATES
Young, Elihu, Sharon, MA, UNITED STATES
PA Genitrix, LLC (U.S. corporation)
PI US 2004151728 A1 20040805
AI US 2003-666834 A1 20030919 (10)
RLI Division of Ser. No. US 2003-645000, filed on 20 Aug 2003, PENDING
PRAI US 2002-404823P 20020820 (60)
US 2003-487407P 20030715 (60)
DT Utility
FS APPLICATION
LN.CNT 39129
INCL INCLM: 424/184.100
INCLS: 424/199.100; 424/200.100; 530/395.000
NCL NCLM: 424/184.100
NCLS: 424/199.100; 424/200.100; 530/395.000
IC [7]
ICM: A61K039-00
ICS: A61K039-12; A61K039-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 2 OF 34 USPATFULL on STN
AN 2004:166195 USPATFULL
TI Novel molecules of the card-related protein family and uses thereof
IN Bertin, John, Watertown, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc., a Massachusetts corporation (U.S. corporation)
PI US 2004127685 A1 20040701
AI US 2004-756097 A1 20040113 (10)
RLI Division of Ser. No. US 2001-841879, filed on 24 Apr 2001, PENDING
Continuation-in-part of Ser. No. US 2000-728721, filed on 1 Dec 2000,
PENDING Continuation-in-part of Ser. No. US 1999-340620, filed on 28 Jun
1999, GRANTED, Pat. No. US 6482933
DT Utility
FS APPLICATION
LN.CNT 3970
INCL INCLM: 530/350.000
INCLS: 530/388.220
NCL NCLM: 530/350.000
NCLS: 530/388.220
IC [7]
ICM: C07K014-705

ICS: C07K016-28

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 3 OF 34 USPATFULL on STN
AN 2004:165307 USPATFULL
TI Lectin compositions and methods for modulating an immune response to an antigen
IN Segal, Andrew H., Boston, MA, UNITED STATES
Young, Elihu, Sharon, MA, UNITED STATES
PA Genitrix, LLC (U.S. corporation)
PI US 2004126793 A1 20040701
AI US 2003-666885 A1 20030919 (10)
RLI Division of Ser. No. US 2003-645000, filed on 20 Aug 2003, PENDING
PRAI US 2002-404823P 20020820 (60)
US 2003-487407P 20030715 (60)
DT Utility
FS APPLICATION
LN.CNT 28979
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 435/419.000; 530/370.000;
530/395.000; 536/023.500
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 435/419.000; 530/370.000;
530/395.000; 536/023.500
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C07K014-47; C07K014-415; C12N005-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 4 OF 34 USPATFULL on STN
AN 2004:164872 USPATFULL
TI Lectin compositions and methods for modulating an immune response to an antigen
IN Segal, Andrew H., Boston, MA, UNITED STATES
Young, Elihu, Sharon, MA, UNITED STATES
PA Genitrix, LLC (U.S. corporation)
PI US 2004126357 A1 20040701
AI US 2003-666886 A1 20030919 (10)
RLI Division of Ser. No. US 2003-645000, filed on 20 Aug 2003, PENDING
PRAI US 2002-404823P 20020820 (60)
US 2003-487407P 20030715 (60)
DT Utility
FS APPLICATION
LN.CNT 39007
INCL INCLM: 424/085.100
INCLS: 424/093.200; 424/185.100
NCL NCLM: 424/085.100
NCLS: 424/093.200; 424/185.100
IC [7]
ICM: A61K048-00
ICS: A61K039-00; A61K038-19
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 5 OF 34 USPATFULL on STN
AN 2004:144196 USPATFULL
TI Antibodies that mimic actions of neurotrophins
IN Clary, Douglas O., San Francisco, CA, UNITED STATES
Weskamp, Gisela, New York, NY, UNITED STATES
Austin, LeeAnn R., San Francisco, CA, UNITED STATES
Reichardt, Louis F., San Francisco, CA, UNITED STATES
PI US 2004109860 A1 20040610
AI US 2004-648619 A1 20040123 (10)
RLI Continuation of Ser. No. US 2001-770949, filed on 26 Jan 2001, GRANTED,
Pat. No. US 6656465 Continuation of Ser. No. US 1998-33313, filed on 2

Mar 1998, ABANDONED Continuation of Ser. No. US 1995-466839, filed on 6
Jun 1995, ABANDONED Continuation of Ser. No. US 1993-162597, filed on 3
Dec 1993, GRANTED, Pat. No. US 5753225

DT Utility
FS APPLICATION

LN.CNT 1864

INCL INCLM: 424/146.100

INCLS: 424/144.100

NCL NCLM: 424/146.100

NCLS: 424/144.100

IC [7]

ICM: A61K039-395

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 6 OF 34 MEDLINE on STN DUPLICATE 1

AN 2004307410 MEDLINE

DN PubMed ID: 15209419

TI The tyrosine phosphatase inhibitor orthovanadate mimics NGF-induced
neuroprotective signaling in rat hippocampal neurons.

AU Gerling Norbert; Culmsee Carsten; Klumpp Susanne; Krieglstein Josef

CS Institute for Pharmacology and Toxicology, Philipps-University Marburg,
Fachbereich Pharmazie, Ketzerbach 63, Marburg D-350372, Germany.

SO Neurochemistry international, (2004 Jun) 44 (7) 505-20.

Journal code: 8006959. ISSN: 0197-0186.

CY England: United Kingdom

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 200407

ED Entered STN: 20040624

Last Updated on STN: 20040729

Entered Medline: 20040728

L4 ANSWER 7 OF 34 USPATFULL on STN

AN 2003:174207 USPATFULL

TI Novel molecules of the card-related protein family and uses thereof

IN Bertin, John, Watertown, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc., a Delaware corporation (U.S.
corporation)

PI US 2003120055 A1 20030626

AI US 2002-295981 A1 20021115 (10)

RLI Division of Ser. No. US 1999-340620, filed on 28 Jun 1999, GRANTED, Pat.
No. US 6482933 Continuation-in-part of Ser. No. US 1999-245281, filed on
5 Feb 1999, GRANTED, Pat. No. US 6369196 Continuation-in-part of Ser.
No. US 1998-207359, filed on 8 Dec 1998, GRANTED, Pat. No. US 6469140
Continuation-in-part of Ser. No. US 1998-99041, filed on 17 Jun 1998,
GRANTED, Pat. No. US 6340576 Continuation-in-part of Ser. No. US
1998-19942, filed on 6 Feb 1998, GRANTED, Pat. No. US 6033855

DT Utility

FS APPLICATION

LN.CNT 8305

INCL INCLM: 536/023.200

INCLS: 530/350.000; 435/069.100; 435/320.100; 435/325.000

NCL NCLM: 536/023.200

NCLS: 530/350.000; 435/069.100; 435/320.100; 435/325.000

IC [7]

ICM: C07H021-04

ICS: C12P021-02; C12N005-06; C07K014-47

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 8 OF 34 USPATFULL on STN

AN 2003:114493 USPATFULL

TI GENE ENCODING NADE, P75NTR-ASSOCIATED CELL DEATH EXECUTOR AND USES
THEREOF

IN SATO, TAKA-AKI, FORT LEE, NJ, UNITED STATES
 PI US 2003079237 A1 20030424
 AI US 1999-327750 A1 19990607 (9)
 DT Utility
 FS APPLICATION
 LN.CNT 2221
 INCL INCLM: 800/008.000
 INCLS: 435/006.000; 435/069.100; 435/226.000; 435/320.100; 536/023.200;
 435/325.000
 NCL NCLM: 800/008.000
 NCLS: 435/006.000; 435/069.100; 435/226.000; 435/320.100; 536/023.200;
 435/325.000
 IC [7]
 ICM: A01K067-00
 ICS: C12Q001-68; C07H021-04; C12N009-64; C12P021-02; C12N005-06
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 9 OF 34 PCTFULL COPYRIGHT 2004 Univentio on STN
 AN 2003045970 PCTFULL ED 20030618 EW 200323
 TIEN NOVEL MOLECULES OF THE CARD RELATED PROTEIN FAMILY AND USES THEREOF
 TIFR MOLECULES DE LA FAMILLE DES PROTEINES SE RELIANT AUX CARD ET
 UTILISATIONS CORRESPONDANTES
 IN BERTIN, John, 475 Arsenal Street, Apt. 1, Watertown, MA 02172, US [US,
 US]
 PA MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney Street, Cambridge, MA
 02139-4169, US [US, US], for all designates States except US;
 BERTIN, John, 475 Arsenal Street, Apt. 1, Watertown, MA 02172, US [US,
 US], for US only
 AG MEIKLEJOHN, Anita, L., Fish & Richardson P.C., 225 Franklin Street,
 Boston, MA 02110-2804, US
 LAF English
 LA English
 DT Patent
 PI WO 2003045970 A1 20030605
 DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU
 CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN
 IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN
 MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ
 TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW
 RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
 RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
 RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL
 PT SE SK TR
 RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
 AI WO 2002-US36510 A 20021112
 PRAI US 2001-09/996,617 20011127
 ICM C07H021-04
 ICS C12Q001-68; G01N033-53

L4 ANSWER 10 OF 34 PCTFULL COPYRIGHT 2004 Univentio on STN
 AN 2003044160 PCTFULL ED 20030610 EW 200322
 TIEN NOVEL MOLECULES OF THE CARD RELATED PROTEIN FAMILY AND USES THEREOF
 TIFR MOLECULES DE LA FAMILLE DE PROTEINES ASSOCIEES AUX CARD ET UTILISATIONS
 CORRESPONDANTES
 IN BERTIN, John, 475 Arsenal Street, Apt. 1, Watertown, MA 02172, US [US,
 US];
 ALNEMRI, Emad, S., 805 Meetinghouse Road, Ambler, PA 19002, US [US, US]
 PA MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney Street, Cambridge, MA
 02139-4169, US [US, US], for all designates States except US;
 THOMAS JEFFERSON UNIVERSITY, 1020 Locust Street, Philadelphia, PA 19107,
 US [US, US], for all designates States except US;
 BERTIN, John, 475 Arsenal Street, Apt. 1, Watertown, MA 02172, US [US,
 US], for US only;
 ALNEMRI, Emad, S., 805 Meetinghouse Road, Ambler, PA 19002, US [US, US],

for US only
AG MEIKLEJOHN, Anita, L., Fish & Richardson P.C., 225 Franklin Street,
Boston, MA 02110-2804, US
LAF English
LA English
DT Patent
PI WO 2003044160 A2 20030530
DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU
CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN
IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN
MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM
TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL
PT SE SK TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
AI WO 2002-US25856 A 20020814
PRAI US 2001-09/931,071 20010815

L4 ANSWER 11 OF 34 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
STN
AN 2003:411146 BIOSIS
DN PREV200300411146
TI Kinetics, activity, and modeling of pan-neurotrophin-1 (PNT-1) with Trk
and p75NTR receptors.
AU Vaghefi, Houman [Reprint Author]; Woo, Sang B.; Walters, D Eric; Neet,
Kenneth E.
CS Biochem and Molec Biol, Finch UHS/Chicago Medical School, 3333 Green Bay
Rd, N. Chicago, IL, 60064, USA
houman.vaghefi@finchcms.edu; woos@finchcms.edu; walterse@finchcms.edu;
neetk@finchcms.edu
SO FASEB Journal, (March 2003) Vol. 17, No. 4-5, pp. Abstract No. 852.32.
http://www.fasebj.org/. e-file.
Meeting Info.: FASEB Meeting on Experimental Biology: Translating the
Genome. San Diego, CA, USA. April 11-15, 2003. FASEB.
ISSN: 0892-6638 (ISSN print).
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 10 Sep 2003
Last Updated on STN: 10 Sep 2003

L4 ANSWER 12 OF 34 USPATFULL on STN
AN 2002:259406 USPATFULL
TI Novel molecules of the card-related protein family and uses thereof
IN Bertin, John, Watertown, MA, UNITED STATES
PI US 2002142979 A1 20021003
US 6756196 B2 20040629
AI US 2001-841879 A1 20010424 (9)
RLI Continuation-in-part of Ser. No. US 2000-728721, filed on 1 Dec 2000,
PENDING Continuation-in-part of Ser. No. US 1999-340620, filed on 28 Jun
1999, PENDING
DT Utility
FS APPLICATION
LN.CNT 3671
INCL INCLM: 514/044.000
INCLS: 536/023.200; 435/006.000; 435/320.100; 435/189.000; 435/069.100;
435/325.000
NCL NCLM: 435/004.000
NCLS: 435/006.000; 435/007.100
IC [7]
ICM: A61K048-00
ICS: C12Q001-68; C07H021-04; C12P021-02; C12N005-06; C12N009-02

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 13 OF 34 USPATFULL on STN
AN 2002:236021 USPATFULL
TI Novel molecules of the card related protein family and uses thereof
IN Bertin, John, Watertown, MA, UNITED STATES
Alnemri, Emad S., Ambler, PA, UNITED STATES
PI US 2002128219 A1 20020912
AI US 2001-931071 A1 20010815 (9)
RLI Continuation-in-part of Ser. No. US 1999-428252, filed on 27 Oct 1999,
ABANDONED
DT Utility
FS APPLICATION
LN.CNT 3511
INCL INCLM: 514/044.000
INCLS: 435/023.000; 435/007.900; 514/012.000
NCL NCLM: 514/044.000
NCLS: 435/023.000; 435/007.900; 514/012.000
IC [7]
ICM: A61K048-00
ICS: A61K038-17; G01N033-53; G01N033-542; C12Q001-37
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 14 OF 34 USPATFULL on STN
AN 2002:236001 USPATFULL
TI Novel molecules of the card-related protein family and uses thereof
IN Bertin, John, Watertown, MA, UNITED STATES
PI US 2002128198 A1 20020912
AI US 2001-996617 A1 20011127 (9)
RLI Continuation-in-part of Ser. No. US 2001-931071, filed on 15 Aug 2001,
PENDING Continuation-in-part of Ser. No. US 1999-428252, filed on 27 Oct
1999, ABANDONED Continuation-in-part of Ser. No. US 1999-340620, filed
on 28 Jun 1999, PENDING
DT Utility
FS APPLICATION
LN.CNT 3208
INCL INCLM: 514/012.000
INCLS: 435/007.900
NCL NCLM: 514/012.000
NCLS: 435/007.900
IC [7]
ICM: A61K038-17
ICS: G01N033-53; G01N033-542
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 15 OF 34 USPATFULL on STN
AN 2002:206144 USPATFULL
TI Method for screening molecules that exert a neurotrophic effect through
activation of neurotrophin receptors
IN Chao, Moses V., New York, NY, UNITED STATES
Lee, Francis S., San Francisco, CA, UNITED STATES
PI US 2002110837 A1 20020815
AI US 2001-982095 A1 20011019 (9)
PRAI US 2000-255887P 20001218 (60)
DT Utility
FS APPLICATION
LN.CNT 1305
INCL INCLM: 435/007.200
NCL NCLM: 435/007.200
IC [7]
ICM: G01N033-53
ICS: G01N033-567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 16 OF 34 USPATFULL on STN
 AN 2002:119857 USPATFULL
 TI Novel molecules of the card-related protein family and uses thereof
 IN Bertin, John, Watertown, MA, UNITED STATES
 PI US 2002061845 A1 20020523
 AI US 2000-728721 A1 20001201 (9)
 RLI Continuation-in-part of Ser. No. US 1999-340620, filed on 28 Jun 1999,
 PENDING Continuation-in-part of Ser. No. US 1999-245281, filed on 5 Feb
 1999, PENDING Continuation-in-part of Ser. No. US 1998-207359, filed on
 8 Dec 1998, PENDING Continuation-in-part of Ser. No. US 1998-99041,
 filed on 17 Jun 1998, PATENTED Continuation-in-part of Ser. No. US
 1998-19942, filed on 6 Feb 1998, PATENTED
 DT Utility
 FS APPLICATION
 LN.CNT 5206
 INCL INCLM: 514/012.000
 INCLS: 514/044.000; 800/008.000; 536/023.200; 435/069.100; 435/325.000;
 435/183.000; 435/320.100
 NCL NCLM: 514/012.000
 NCLS: 514/044.000; 800/008.000; 536/023.200; 435/069.100; 435/325.000;
 435/183.000; 435/320.100
 IC [7]
 ICM: A61K038-17
 ICS: A61K048-00; A01K067-00; C07H021-04; C12N009-00; C12P021-02;
 C12N005-06
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 17 OF 34 USPATFULL on STN
 AN 2002:119845 USPATFULL
 TI Novel molecules of the card-related protein family and uses thereof
 IN Bertin, John, Watertown, MA, UNITED STATES
 Chao, Moses V., New York, NY, UNITED STATES
 PI US 2002061833 A1 20020523
 US 6680167 B2 20040120
 AI US 2000-748537 A1 20001226 (9)
 RLI Continuation-in-part of Ser. No. US 1998-99041, filed on 17 Jun 1998,
 PENDING Continuation-in-part of Ser. No. US 1998-19942, filed on 6 Feb
 1998, GRANTED, Pat. No. US 6033855
 DT Utility
 FS APPLICATION
 LN.CNT 3159
 INCL INCLM: 514/001.000
 INCLS: 435/007.210
 NCL NCLM: 435/004.000
 NCLS: 436/006.000; 536/023.100
 IC [7]
 ICM: A61K031-00
 ICS: G01N033-567
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 18 OF 34 USPATFULL on STN
 AN 2002:105672 USPATFULL
 TI Antibodies that mimic actions of neurotrophins
 IN Clary, Douglas O., San Francisco, CA, UNITED STATES
 Weskamp, Gisela, New York, NY, UNITED STATES
 Austin, Leeann R., San Francisco, CA, UNITED STATES
 Reichardt, Louis F., San Francisco, CA, UNITED STATES
 PA The Regents of the University of California (U.S. corporation)
 PI US 2002054874 A1 20020509
 US 6656465 B2 20031202
 AI US 2001-770949 A1 20010126 (9)
 RLI Continuation of Ser. No. US 1998-33313, filed on 2 Mar 1998, ABANDONED
 Continuation of Ser. No. US 1995-466839, filed on 6 Jun 1995, ABANDONED
 Continuation of Ser. No. US 1993-162597, filed on 3 Dec 1993, GRANTED,

Pat. No. US 5753225
DT Utility
FS APPLICATION
LN.CNT 1837
INCL INCLM: 424/143.100
NCL NCLM: 424/130.100
NCLS: 424/138.100; 424/141.100; 424/143.100; 424/156.100; 530/387.100;
530/388.100; 530/388.220
IC [7]
ICM: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 19 OF 34 USPATFULL on STN
AN 2002:304069 USPATFULL
TI Molecules of the card-related protein family and uses thereof
IN Bertin, John, Watertown, MA, United States
PA Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 6482933 B1 20021119
AI US 1999-340620 19990628 (9)
RLI Continuation-in-part of Ser. No. US 1999-245281, filed on 5 Feb 1999
Continuation-in-part of Ser. No. US 1998-207359, filed on 8 Dec 1998
Continuation-in-part of Ser. No. US 1998-99041, filed on 17 Jun 1998
Continuation-in-part of Ser. No. US 1998-19942, filed on 6 Feb 1998
DT Utility
FS GRANTED
LN.CNT 8371
INCL INCLM: 536/023.100
INCLS: 435/006.000; 435/320.100; 435/252.100; 435/252.300; 435/325.000;
435/352.000; 536/024.330; 536/023.500; 536/024.300
NCL NCLM: 536/023.100
NCLS: 435/006.000; 435/252.100; 435/252.300; 435/320.100; 435/325.000;
435/352.000; 536/023.500; 536/024.300; 536/024.330
IC [7]
ICM: C07H021-04
ICS: C12N015-11; C12N015-63; C12N015-85
EXF 536/23.1; 536/24.33; 536/23.5; 536/24.3; 435/6; 435/320.1; 435/252.1;
435/252.3; 435/325; 435/352
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 20 OF 34 PCTFULL COPYRIGHT 2004 Univentio on STN
AN 2002053765 PCTFULL ED 20020723 EW 200228
TIEN NOVEL MOLECULES OF THE CARD-RELATED PROTEIN FAMILY AND USED THEREOF
TIFR NOUVELLES MOLECULES DE LA FAMILLE DES PROTEINES LIEES AU CARD ET
UTILISATION DE CELLES-CI
IN BERTIN, John, 475 Arsenal Street, Apt. 1, Watertown, MA 02172, US [US,
US];
PHILPOTT, Dana, Paris, FR, FR;
SANSONETTI, Philippe, Paris, FR, FR;
GIRARDIN, Stephen, Paris, FR, FR
PA MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney Street, Cambridge, MA
02139-4169, US [US, US], for all designates States except US;
BERTIN, John, 475 Arsenal Street, Apt. 1, Watertown, MA 02172, US [US,
US], for US only;
PHILPOTT, Dana, Paris, FR, FR, for US only;
SANSONETTI, Philippe, Paris, FR, FR, for US only;
GIRARDIN, Stephen, Paris, FR, FR, for US only
AG MEIKLEJOHN, Anita, L., Fish & Rickardson, P.C., 225 Franklin Street,
Boston, MA 02110-2804, US
LAF English
LA English
DT Patent
PI WO 2002053765 A1 20020711
DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU

CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN
 IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN
 MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM
 TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW
 RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
 RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
 RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
 RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
 AI WO 2001-US49798 A 20011220
 PRAI US 2000-60/258,724 20001229
 ICM C12Q001-00
 ICS G01N033-53; G01N033-537; G01N033-543; G01N033-567; C07K001-00;
 C07K014-00; C07K017-00

 L4 ANSWER 21 OF 34 PCTFULL COPYRIGHT 2004 Univentio on STN
 AN 2002044354 PCTFULL ED 20020624 EW 200223
 TIEN NOVEL MOLECULES OF THE CARD-RELATED PROTEIN FAMILY AND USES THEREOF
 TIFR NOUVELLES MOLECULES DE LA FAMILLE DE PROTEINES RELATIVES A CARD ET LEURS
 UTILISATIONS
 IN BERTIN, John, 475 Arsenal Street, Apt. 1, Watertown, MA 02172, US [US,
 US]
 PA MILLENIUM PHARMACEUTICALS, INC., 75 Sidney Street, Cambridge, MA 01239,
 US [US, US], for all designates States except US;
 BERTIN, John, 475 Arsenal Street, Apt. 1, Watertown, MA 02172, US [US,
 US], for US only
 AG MEIKLEJOHN, Anita, L., Fish & Rickardson, P.C., 225 Franklin Street,
 Boston, MA 02110-2804, US
 LAF English
 LA English
 DT Patent
 PI WO 2002044354 A2 20020606
 DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU
 CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN
 IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN
 MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM
 TR TT TZ UA UG US UZ VN YU ZA ZM ZW
 RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
 RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
 RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
 RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
 AI WO 2001-US44894 A 20011129
 PRAI US 2000-09/728,721 20001201
 US 2001-09/841,879 20010424
 ICM C12N009-00

 L4 ANSWER 22 OF 34 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
 STN
 AN 2003:303952 BIOSIS
 DN PREV200300303952
 TI NRIF, A PROAPOPTOTIC PROTEIN, IS REQUIRED FOR P75 - MEDIATED CELL DEATH.
 AU Linggi, M. S. [Reprint Author]; Burke, T. L. [Reprint Author]; Gentry, J.
 J. [Reprint Author]; Carter, B. D. [Reprint Author]
 CS Biochemistry, Ctr. Molecular Neuroscience, Vanderbilt University,
 Nashville, TN, USA
 SO Society for Neuroscience Abstract Viewer and Itinerary Planner, (2002)
 Vol. 2002, pp. Abstract No. 426.15. <http://sfn.scholarone.com>. cd-rom.
 Meeting Info.: 32nd Annual Meeting of the Society for Neuroscience.
 Orlando, Florida, USA. November 02-07, 2002. Society for Neuroscience.
 DT Conference; (Meeting)
 Conference; (Meeting Poster)
 Conference; Abstract; (Meeting Abstract)
 LA English
 ED Entered STN: 2 Jul 2003
 Last Updated on STN: 2 Jul 2003

L4 ANSWER 23 OF 34 PCTFULL COPYRIGHT 2004 Univentio on STN
 AN 2001030813 PCTFULL ED 20020820
 TIEN NOVEL MOLECULES OF THE CARD-RELATED PROTEIN FAMILY AND USES THEREOF
 TIFR NOUVELLES MOLECULES DE LA FAMILLE DE LA PROTEINE APPARENTEE A CARD, ET
 UTILISATION DESDITES MOLECULES
 IN BERTIN, John
 PA MILLENNIUM PHARMACEUTICALS, INC.;
 BERTIN, John
 DT Patent
 PI WO 2001030813 A1 20010503
 DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ
 DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP
 KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX
 MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA
 UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW
 AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB
 GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR
 NE SN TD TG
 AI WO 2000-US29796 A 20001027
 PRAI US 1999-09/428,252 19991027
 ICM C07K014-00

L4 ANSWER 24 OF 34 PCTFULL COPYRIGHT 2004 Univentio on STN
 AN 2001000826 PCTFULL ED 20020828
 TIEN NOVEL MOLECULES OF THE CARD-RELATED PROTEIN FAMILY AND USES THEREOF
 TIFR NOUVELLES MOLECULES DE LA FAMILLE DE PROTEINES LIEE A LA CARD ET
 UTILISATIONS DE CES DERNIERES
 IN BERTIN, John
 PA MILLENNIUM PHARMACEUTICALS, INC.;
 BERTIN, John
 DT Patent
 PI WO 2001000826 A2 20010104
 DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ
 DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP
 KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX
 MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA
 UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW
 AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB
 GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR
 NE SN TD TG
 AI WO 2000-US17691 A 20000628
 PRAI US 1999-09/340,620 19990628
 ICM C12N015-12
 ICS C07K014-47; C12N005-10; C07K016-18; G01N033-50; G01N033-53

L4 ANSWER 25 OF 34 MEDLINE on STN DUPLICATE 2
 AN 2001528560 MEDLINE
 DN PubMed ID: 11544482
 TI Neurotrophins use the Erk5 pathway to mediate a retrograde survival
 response.
 CM Comment in: Nat Neurosci. 2001 Oct;4(10):963-4. PubMed ID: 11574825
 Erratum in: Nat Neurosci 2002 Oct;5(10):1017
 AU Watson F L; Heerssen H M; Bhattacharyya A; Klesse L; Lin M Z; Segal R A
 CS Department of Neurobiology, Harvard Medical School, Dana 620, Dana-Farber
 Cancer Institute, Boston, Massachusetts 02115, USA.
 NC NS35148 (NINDS)
 SO Nature neuroscience, (2001 Oct) 4 (10) 981-8.
 Journal code: 9809671. ISSN: 1097-6256.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200110

ED Entered STN: 20011001
Last Updated on STN: 20021023
Entered Medline: 20011025

L4 ANSWER 26 OF 34 MEDLINE on STN DUPLICATE 3
AN 2001574621 MEDLINE
DN PubMed ID: 11681842
TI **Neurotrophin receptor TrkB activation** is not
required for the postnatal **survival** of retinal ganglion cells in
vivo.
AU Rohrer B; LaVail M M; Jones K R; Reichardt L F
CS Howard Hughes Medical Institute, University of California at San
Francisco, San Francisco, California 94143, USA.. rohrer@musc.edu
NC EY01919 (NEI)
EY02162 (NEI)
EY11349 (NEI)
NS P01-16033 (NINDS)
SO Experimental neurology, (2001 Nov) 172 (1) 81-91.
Journal code: 0370712. ISSN: 0014-4886.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200112
ED Entered STN: 20011030
Last Updated on STN: 20020123
Entered Medline: 20011205

L4 ANSWER 27 OF 34 PCTFULL COPYRIGHT 2004 Univentio on STN
AN 2000075278 PCTFULL ED 20020515
TIEN GENE ENCODING NADE, P75NTR¿-ASSOCIATED CELL DEATH EXECUTOR AND
USES THEREOF
TIFR GENE CODANT POUR NADE OU ACTIVATEUR DE MORT CELLULAIRE ASSOCIE A P75NTR
ET PROCEDE DE SON UTILISATION
IN SATO, Taka-AkiRP : WHITE, John, P.
PA THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK;
SATO, Taka-Aki
LA English
DT Patent
PI WO 2000075278 A2 20001214
DS W:
AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK
DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP
KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ
PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ
VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY
KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT
LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD
TG
AI WO 2000-US15621 A 20000607
PRAI US 1999-09/327,750 19990607

L4 ANSWER 28 OF 34 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
STN
AN 2001:97056 BIOSIS
DN PREV200100097056
TI **Neurotrophin receptor TrkB activation** is not
required for postnatal **survival** of retinal ganglion cells (RGC).
AU Rohrer, B. [Reprint author]; LaVail, M. M.; Jones, K. R.; Reichardt, L. F.
CS Howard Hughes Medical Institute, San Francisco, CA, USA
SO Society for Neuroscience Abstracts, (2000) Vol. 26, No. 1-2, pp. Abstract
No.-307.3. print.
Meeting Info.: 30th Annual Meeting of the Society of Neuroscience. New
Orleans, LA, USA. November 04-09, 2000. Society for Neuroscience.
ISSN: 0190-5295.

DT Conference; (Meeting)
 Conference; Abstract; (Meeting Abstract)
 LA English
 ED Entered STN: 21 Feb 2001
 Last Updated on STN: 15 Feb 2002

L4 ANSWER 29 OF 34 USPATFULL on STN
 AN 1998:54480 USPATFULL
 TI Antibodies that mimic actions of neurotrophins
 IN Clary, Douglas O., San Francisco, CA, United States
 Weskamp, Gisela, New York, NY, United States
 Austin, Leeann R., San Francisco, CA, United States
 Reichardt, Louis F., San Francisco, CA, United States
 PA The Regents of the University of California, Oakland, CA, United States
 (U.S. corporation)
 PI US 5753225 19980519
 AI US 1993-162597 19931203 (8)
 DT Utility
 FS Granted
 LN.CNT 1850
 INCL INCLM: 424/130.100
 INCLS: 424/141.100; 424/143.100; 424/156.100; 530/387.100; 530/388.100;
 530/388.220
 NCL NCLM: 424/130.100
 NCLS: 424/141.100; 424/143.100; 424/156.100; 530/387.100; 530/388.100;
 530/388.220
 IC [6]
 ICM: A61K039-395
 ICS: C07K016-00
 EXF 435/244; 424/130.1; 424/143.1; 530/388.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 30 OF 34 MEDLINE on STN DUPLICATE 4
 AN 1999069491 MEDLINE
 DN PubMed ID: 9852160
 TI p53 is essential for developmental neuron death as regulated by the TrkA
 and p75 neurotrophin receptors.
 AU Aloyz R S; Bamji S X; Pozniak C D; Toma J G; Atwal J; Kaplan D R; Miller F
 D
 CS Center for Neuronal Survival, Montreal Neurological Institute, McGill
 University, Montreal, Quebec, Canada H3A 2B4.
 SO Journal of cell biology, (1998 Dec 14) 143 (6) 1691-703.
 Journal code: 0375356. ISSN: 0021-9525.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199901
 ED Entered STN: 19990209
 Last Updated on STN: 20020420
 Entered Medline: 19990126

L4 ANSWER 31 OF 34 MEDLINE on STN
 AN 97461759 MEDLINE
 DN PubMed ID: 9316034
 TI Blocking nerve growth factor binding to the p75 neurotrophin
receptor on sympathetic neurons transiently reduces trkA
activation but does not affect neuronal **survival**.
 AU Lachance C; Belliveau D J; Barker P A
 CS Center for Neuronal Survival, Montreal Neurological Institute, McGill
 University, Quebec, Canada.
 SO Neuroscience, (1997 Dec) 81 (3) 861-71.
 Journal code: 7605074. ISSN: 0306-4522.
 CY United States

DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199711
ED Entered STN: 19971224
Last Updated on STN: 20000303
Entered Medline: 19971124

L4 ANSWER 32 OF 34 PCTFULL COPYRIGHT 2004 Univentio on STN
AN 1995015180 PCTFULL ED 20020514
TIEN ANTIBODIES THAT MIMIC ACTIONS OF NEUROTROPHINS
TIFR ANTICORPS IMITANT LES EFFETS DES NEUROTROPHINES
IN CLARY, Douglas, O.;
WESKAMP, Gisela;
AUSTIN, Leeann;
REICHARDT, Louis, F.
PA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
LA English
DT Patent
PI WO 9515180 A1 19950608
DS W: AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU
JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW NL NO NZ PL
PT RO RU SD SE SI SK TJ TT UA UZ VN KE MW SD SZ AT BE CH
DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM
GA GN ML MR NE SN TD TG
AI WO 1994-US13708 A 19941201
PRAI US 1993-8/162,597 19931203
ICM A61K039-395
ICS C07K016:28; C12N001:38; G01N033:53

L4 ANSWER 33 OF 34 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
STN
AN 1995:1739 BIOSIS
DN PREV199598016039
TI Monoamine-**activated** alpha-2-macroglobulin inhibits neurite
outgrowth, **survival**, choline acetyltransferase, and dopamine
concentration of neurons by blocking **neurotrophin-**
receptor (trk) phosphorylation and signal transduction.
AU Koo, Peter H. [Reprint author]; Liebl, Daniel J. [Reprint author]; Qiu,
Wan-Song [Reprint author]; Hu, Yi-Qun [Reprint author]; Dluzen, Dean E.
CS Dep. Microbiol. Immunology, Northeastern Ohio Univ. Coll. Med., Rootstown,
OH 44272, USA
SO Borth, W. [Editor]; Feinman, R. D. [Editor]; Gonias, S. L. [Editor];
Quigley, J. P. [Editor]; Strickland, D. K. [Editor]. Ann. N. Y. Acad.
Sci., (1994) pp. 460-464. Annals of the New York Academy of Sciences;
Biology of alpha 2-macroglobulin, its receptor, and related proteins.
Publisher: New York Academy of Sciences, 2 East 63rd Street, New York, New
York 10021, USA. Series: Annals of the New York Academy of Sciences.
Meeting Info.: Conference. Woods Hole, Massachusetts, USA. October 11-14,
1993.
CODEN: ANYAA9. ISSN: 0077-8923. ISBN: 0-89766-887-1 (paper), 0-89766-886-3
(cloth).
DT Book
Conference; (Meeting)
Book; (Book Chapter)
Conference; (Meeting Paper)
LA English
ED Entered STN: 5 Jan 1995
Last Updated on STN: 5 Jan 1995

L4 ANSWER 34 OF 34 MEDLINE on STN
AN 95030797 MEDLINE
DN PubMed ID: 7524422
TI Monoamine-**activated** alpha 2-macroglobulin inhibits neurite

outgrowth, **survival**, choline acetyltransferase, and dopamine concentration of neurons by blocking **neurotrophin-receptor** (trk) phosphorylation and signal transduction.

AU Koo P H; Liebl D J; Qiu W S; Hu Y Q; Dluzen D E
CS Department of Microbiology and Immunology, Northeastern Ohio Universities
College of Medicine, Rootstown 44272.
NC NS-30698 (NINDS)
SO Annals of the New York Academy of Sciences, (1994 Sep 10) 737 460-4.
Journal code: 7506858. ISSN: 0077-8923.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199411
ED Entered STN: 19941222
Last Updated on STN: 20000303
Entered Medline: 19941114

=> d hist

(FILE 'HOME' ENTERED AT 14:55:59 ON 21 OCT 2004)

FILE 'MEDLINE, BIOSIS, USPATFULL, PCTFULL' ENTERED AT 14:56:27 ON 21 OCT 2004

L1 3567 S NEUROTROPHI# RECEPTOR#
L2 262 S L1 (20A) ACTIVAT###
L3 38 S L2 (40A) SURVIVAL
L4 34 DUPLICATE REMOVE L3 (4 DUPLICATES REMOVED)

=> s l4 and (phosphotyrosine (12a) antibod###)

L5 5 L4 AND (PHOSPHOTYROSINE (12A) ANTIBOD###)

=> d 1-5

L5 ANSWER 1 OF 5 USPATFULL on STN
AN 2004:144196 USPATFULL
TI Antibodies that mimic actions of neurotrophins
IN Clary, Douglas O., San Francisco, CA, UNITED STATES
Weskamp, Gisela, New York, NY, UNITED STATES
Austin, LeeAnn R., San Francisco, CA, UNITED STATES
Reichardt, Louis F., San Francisco, CA, UNITED STATES
PI US 2004109860 A1 20040610
AI US 2004-648619 A1 20040123 (10)
RLI Continuation of Ser. No. US 2001-770949, filed on 26 Jan 2001, GRANTED,
Pat. No. US 6656465 Continuation of Ser. No. US 1998-33313, filed on 2
Mar 1998, ABANDONED Continuation of Ser. No. US 1995-466839, filed on 6
Jun 1995, ABANDONED Continuation of Ser. No. US 1993-162597, filed on 3
Dec 1993, GRANTED, Pat. No. US 5753225
DT Utility
FS APPLICATION
LN.CNT 1864
INCL INCLM: 424/146.100
INCLS: 424/144.100
NCL NCLM: 424/146.100
NCLS: 424/144.100
IC [7]
ICM: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 2 OF 5 USPATFULL on STN
AN 2002:206144 USPATFULL
TI Method for screening molecules that exert a neurotrophic effect through
activation of neurotrophin receptors

IN Chao, Moses V., New York, NY, UNITED STATES
Lee, Francis S., San Francisco, CA, UNITED STATES
PI US 2002110837 A1 20020815
AI US 2001-982095 A1 20011019 (9)
PRAI US 2000-255887P 20001218 (60)
DT Utility
FS APPLICATION
LN.CNT 1305
INCL INCLM: 435/007.200
NCL NCLM: 435/007.200
IC [7]
ICM: G01N033-53
ICS: G01N033-567

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 3 OF 5 USPATFULL on STN
AN 2002:105672 USPATFULL
TI Antibodies that mimic actions of neurotrophins
IN Clary, Douglas O., San Francisco, CA, UNITED STATES
Weskamp, Gisela, New York, NY, UNITED STATES
Austin, Leeann R., San Francisco, CA, UNITED STATES
Reichardt, Louis F., San Francisco, CA, UNITED STATES
PA The Regents of the University of California (U.S. corporation)
PI US 2002054874 A1 20020509
US 6656465 B2 20031202
AI US 2001-770949 A1 20010126 (9)
RLI Continuation of Ser. No. US 1998-33313, filed on 2 Mar 1998, ABANDONED
Continuation of Ser. No. US 1995-466839, filed on 6 Jun 1995, ABANDONED
Continuation of Ser. No. US 1993-162597, filed on 3 Dec 1993, GRANTED,
Pat. No. US 5753225
DT Utility
FS APPLICATION
LN.CNT 1837
INCL INCLM: 424/143.100
NCL NCLM: 424/130.100
NCLS: 424/138.100; 424/141.100; 424/143.100; 424/156.100; 530/387.100;
530/388.100; 530/388.220
IC [7]
ICM: A61K039-395

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 5 USPATFULL on STN
AN 1998:54480 USPATFULL
TI Antibodies that mimic actions of neurotrophins
IN Clary, Douglas O., San Francisco, CA, United States
Weskamp, Gisela, New York, NY, United States
Austin, Leeann R., San Francisco, CA, United States
Reichardt, Louis F., San Francisco, CA, United States
PA The Regents of the University of California, Oakland, CA, United States
(U.S. corporation)
PI US 5753225 19980519
AI US 1993-162597 19931203 (8)
DT Utility
FS Granted
LN.CNT 1850
INCL INCLM: 424/130.100
INCLS: 424/141.100; 424/143.100; 424/156.100; 530/387.100; 530/388.100;
530/388.220
NCL NCLM: 424/130.100
NCLS: 424/141.100; 424/143.100; 424/156.100; 530/387.100; 530/388.100;
530/388.220
IC [6]
ICM: A61K039-395
ICS: C07K016-00

EXF 435/244; 424/130.1; 424/143.1; 530/388.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 5 PCTFULL COPYRIGHT 2004 Univentio on STN
AN 1995015180 PCTFULL ED 20020514
TIEN ANTIBODIES THAT MIMIC ACTIONS OF NEUROTROPHINS
TIFR ANTICORPS IMITANT LES EFFETS DES NEUROTROPHINES
IN CLARY, Douglas, O.;
WESKAMP, Gisela;
AUSTIN, Leeann;
REICHARDT, Louis, F.
PA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
LA English
DT Patent
PI WO 9515180 A1 19950608
DS W: AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU
JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW NL NO NZ PL
PT RO RU SD SE SI SK TJ TT UA UZ VN KE MW SD SZ AT BE CH
DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM
GA GN ML MR NE SN TD TG
AI WO 1994-US13708 A 19941201
PRAI US 1993-8/162,597 19931203
ICM A61K039-395
ICS C07K016:28; C12N001:38; G01N033:53

=> d 4 hit

L5 ANSWER 4 OF 5 USPATFULL on STN
SUMM Thus, the invention provides immunoglobulins that mimic the actions of neurotrophins. Appropriately designed immunoglobulins able to dimerize the **neurotrophin-receptors** can **activate** these receptors and serve as neuronal **survival** and differentiation-promoting agents. Such immunoglobulins are easier to prepare, are more stable, and are likely to be longer acting than neurotrophins. In some cases immunoglobulins can be designed to act with greater selectivity than certain neurotrophins, several of which recognize more than one receptor. Bifunctional organic molecules that bind neurotrophin receptors are likely to also activate these receptors.

DETD The anti-**phosphotyrosine** monoclonal **antibody** 4G10, purchased from Upstate Biologicals Inc., was used at 1 µg/ml, followed by rabbit anti-mouse antibody, purchased from Organon Teknika Corp., coupled to HRP diluted 1:5000.

DETD PC12 cells respond to NGF rapidly, and after five minutes of exposure, a reproducible burst of tyrosine phosphorylation of many cellular proteins occurs (Maher, P. A., Proc. Natl. Acad. Sci. USA 85:6788-6791 (1988)). This effect can be measured by probing blots of cell lysates with anti-**phosphotyrosine antibodies**. In lane 2 several cellular substrates for NGF-dependent tyrosine phosphorylation are detected after five minutes of NGF treatment (arrows), but not in the absence of NGF (lane 1).

DETD To show that the RtrkA.EX IgG effects reflected activation of the trkA receptor, effects of NGF and various **antibodies** on trkA **phosphotyrosine** levels were examined. TrkA is a tyrosine kinase receptor which has been shown previously to be tyrosine phosphorylated and activated upon binding of NGF (Kaplan, et al., 1991b; Klein, et al., 1991). Therefore, PC12 cultures were treated as above with NGF, or antibody preparations, and then immunoprecipitated the trkA receptor from the corresponding lysates. The precipitates were analyzed by blotting with the anti-**phosphotyrosine antibody**.

=> s 11 and (phosphotyrosine (12a) antibod###)

L6 116 L1 AND (PHOSPHOTYROSINE (12A) ANTIBOD###)

=> s 12 and (phosphotyrosine (12a) antibod###)

L7 19 L2 AND (PHOSPHOTYROSINE (12A) ANTIBOD###)

=> duplicate remove

ENTER L# LIST OR (END):17

DUPLICATE PREFERENCE IS 'BIOSIS, USPATFULL, PCTFULL'

KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n

PROCESSING COMPLETED FOR L7

L8 19 DUPLICATE REMOVE L7 (0 DUPLICATES REMOVED)

=> d 1-19

L8 ANSWER 1 OF 19 USPATFULL on STN

AN 2004:145039 USPATFULL

TI Novel treatment of neurodegenerative diseases by altering levels of TrkB isoforms and/or TrkC isoforms

IN Krueger, Bruce K., Ellicott City, MD, UNITED STATES

Kingsbury, Tami J., Baltimore, MD, UNITED STATES

Bambrick, Linda L., Baltimore, MD, UNITED STATES

Dorsey, Susan G., Frederick, MD, UNITED STATES

PA University of Maryland, Baltimore (U.S. corporation)

PI US 2004110711 A1 20040610

AI US 2003-645546 A1 20030822 (10)

PRAI WO 2002-US16807 20020528

WO 2002-US5151 20020222

DT Utility

FS APPLICATION

LN.CNT 3403

INCL INCLM: 514/044.000

NCL NCLM: 514/044.000

IC [7]

ICM: A61K048-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 2 OF 19 USPATFULL on STN

AN 2004:144196 USPATFULL

TI Antibodies that mimic actions of neurotrophins

IN Clary, Douglas O., San Francisco, CA, UNITED STATES

Weskamp, Gisela, New York, NY, UNITED STATES

Austin, LeeAnn R., San Francisco, CA, UNITED STATES

Reichardt, Louis F., San Francisco, CA, UNITED STATES

PI US 2004109860 A1 20040610

AI US 2004-648619 A1 20040123 (10)

RLI Continuation of Ser. No. US 2001-770949, filed on 26 Jan 2001, GRANTED, Pat. No. US 6656465 Continuation of Ser. No. US 1998-33313, filed on 2 Mar 1998, ABANDONED Continuation of Ser. No. US 1995-466839, filed on 6 Jun 1995, ABANDONED Continuation of Ser. No. US 1993-162597, filed on 3 Dec 1993, GRANTED, Pat. No. US 5753225

DT Utility

FS APPLICATION

LN.CNT 1864

INCL INCLM: 424/146.100

INCLS: 424/144.100

NCL NCLM: 424/146.100

NCLS: 424/144.100

IC [7]

ICM: A61K039-395

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 3 OF 19 USPATFULL on STN

AN 2004:109947 USPATFULL

TI Pharmaceutical compositions comprising porphyrins and some novel

porphyrin derivatives
 IN Yayon, Avner, Moshav Sitria, ISRAEL
 Aviezer, David, Hashmonaim, ISRAEL
 Gross, Zeev, Petach Tikva, ISRAEL
 PA Yeda Research and Development Co. Ltd., Rehovot, ISRAEL (non-U.S.
 corporation)
 Technion Research and Development Foundation Ltd., Haifa, ISRAEL
 (non-U.S. corporation)
 PI US 6730666 B1 20040504
 WO 2000027379 20000518
 AI US 2001-831305 20010718 (9)
 WO 1999-IL602 19991108
 PRAI IL 1998-126953 19981108
 DT Utility
 FS GRANTED
 LN.CNT 2086
 INCL INCLM: 514/183.000
 INCLS: 514/185.000; 534/010.000; 540/121.000; 540/145.000; 540/465.000;
 540/471.000; 540/474.000
 NCL NCLM: 514/183.000
 NCLS: 514/185.000; 534/010.000; 540/121.000; 540/145.000; 540/465.000;
 540/471.000; 540/474.000
 IC [7]
 ICM: A61K038-41
 ICS: C07D487-22
 EXF 514/183; 514/185; 540/121; 540/145; 540/465; 540/471; 540/474; 534/10
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 4 OF 19 PCTFULL COPYRIGHT 2004 Univentio on STN
 AN 2003071872 PCTFULL ED 20030915 EW 200336
 TIEN NOVEL TREATMENT OF NEURODEGENERATIVE DISEASES BY ALTERING LEVELS OF TRKB
 ISOFORMS AND/OR TRKC ISOFORMS
 TIFR NOUVEAU TRAITEMENT DE MALADIES NEURODEGENERATIVES PAR MODIFICATION DE
 NIVEAUX D'ISOFORMES TRKB ET/OU TRKC
 IN KRUEGER, Bruce, K., 4085 Fragile Sail Way, Ellicott City, MD 21042, US
 [US, US];
 KINGSBURY, Tami, J., 622 Walker Avenue, Baltimore, MD 21212, US [US,
 US];
 BAMBRICK, Linda, L., 1912 Sulgrave Avenue, Baltimore, MD 21209, US [US,
 US];
 DORSEY, Susan, G., 937 Jubal Way, Frederick, MD 21701, US [US, US]
 PA UNIVERSITY OF MARYLAND, BALTIMORE, TEC COM / ORD, 520 West Lombard
 Street, Baltimore, MD 21201, US [US, US], for all designates States
 except US;
 KRUEGER, Bruce, K., 4085 Fragile Sail Way, Ellicott City, MD 21042, US
 [US, US];
 KINGSBURY, Tami, J., 622 Walker Avenue, Baltimore, MD 21212, US [US,
 US];
 BAMBRICK, Linda, L., 1912 Sulgrave Avenue, Baltimore, MD 21209, US [US,
 US];
 DORSEY, Susan, G., 937 Jubal Way, Frederick, MD 21701, US [US, US]
 AG MARKS, David, L., University of Maryland, Baltimore, Office of Research
 and Development, 515 West Lombard Street, 5th Floor, Baltimore, MD
 21201, US
 LAF English
 LA English
 DT Patent
 PI WO 2003071872 A1 20030904
 DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU
 CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN
 IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN
 MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM
 TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW
 RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW

RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
 RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
 RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
 AI WO 2002-US16807 A 20020528
 PRAI US 2002-PCT/US02/05151 20020222
 ICM A01N043-04
 ICS A01N063-00; A01N065-00; A61K031-70

L8 ANSWER 5 OF 19 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
 STN
 AN 2004:146047 BIOSIS
 DN PREV200400145866
 TI TrkA phosphorylation is enhanced in sympathetic neurons from p75
 neurotrophin receptor exon III null mutant mice.
 AU Hannila, S. S. [Reprint Author]; Lawrance, G. M.; Ross, G. M.; Kawaja, M.
 D.
 CS Dept. of Anat. and Cell. Biol., Queen's Univ., Kingston, ON, Canada
 SO Society for Neuroscience Abstract Viewer and Itinerary Planner, (2003)
 Vol. 2003, pp. Abstract No. 786.19. <http://sfn.scholarone.com>. e-file.
 Meeting Info.: 33rd Annual Meeting of the Society of Neuroscience. New
 Orleans, LA, USA. November 08-12, 2003. Society of Neuroscience.
 DT Conference; (Meeting)
 Conference; Abstract; (Meeting Abstract)
 LA English
 ED Entered STN: 17 Mar 2004
 Last Updated on STN: 17 Mar 2004

L8 ANSWER 6 OF 19 USPATFULL on STN
 AN 2002:221850 USPATFULL
 TI Potentiator for neurotrophin effect
 IN Isono, Fujio, Urayasu-shi, JAPAN
 Fujii, Miyuki, Tokyo, JAPAN
 Aoyagi, Atsushi, Tokyo, JAPAN
 PA SANKO COMPANY, LIMITED, Tokyo, JAPAN (non-U.S. corporation)
 PI US 2002119993 A1 20020829
 AI US 2001-981367 A1 20011016 (9)
 RLI Continuation of Ser. No. WO 2000-JP2534, filed on 19 Apr 2000, UNKNOWN
 PRAI JP 1999-110766 19990419
 DT Utility
 FS APPLICATION
 LN.CNT 972
 INCL INCLM: 514/298.000
 NCL NCLM: 514/298.000
 IC [7]
 ICM: A61K031-473

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 7 OF 19 USPATFULL on STN
 AN 2002:206144 USPATFULL
 TI Method for screening molecules that exert a neurotrophic effect through
activation of neurotrophin receptors
 IN Chao, Moses V., New York, NY, UNITED STATES
 Lee, Francis S., San Francisco, CA, UNITED STATES
 PI US 2002110837 A1 20020815
 AI US 2001-982095 A1 20011019 (9)
 PRAI US 2000-255887P 20001218 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1305
 INCL INCLM: 435/007.200
 NCL NCLM: 435/007.200
 IC [7]
 ICM: G01N033-53
 ICS: G01N033-567

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 8 OF 19 USPATFULL on STN
AN 2002:156704 USPATFULL
TI Hair cell disorders
IN Gao, Wei-Qiang, Foster City, CA, UNITED STATES
PI US 2002081299 A1 20020627
AI US 2001-849868 A1 20010504 (9)
PRAI US 1998-107522P 19981107 (60)
DT Utility
FS APPLICATION
LN.CNT 5225
INCL INCLM: 424/145.100
INCLS: 424/093.700; 514/012.000
NCL NCLM: 424/145.100
NCLS: 424/093.700; 514/012.000
IC [7]
ICM: A61K039-395
ICS: A61K038-17

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 9 OF 19 USPATFULL on STN
AN 2002:105672 USPATFULL
TI Antibodies that mimic actions of neurotrophins
IN Clary, Douglas O., San Francisco, CA, UNITED STATES
Weskamp, Gisela, New York, NY, UNITED STATES
Austin, Leeann R., San Francisco, CA, UNITED STATES
Reichardt, Louis F., San Francisco, CA, UNITED STATES
PA The Regents of the University of California (U.S. corporation)
PI US 2002054874 A1 20020509
US 6656465 B2 20031202
AI US 2001-770949 A1 20010126 (9)
RLI Continuation of Ser. No. US 1998-33313, filed on 2 Mar 1998, ABANDONED
Continuation of Ser. No. US 1995-466839, filed on 6 Jun 1995, ABANDONED
Continuation of Ser. No. US 1993-162597, filed on 3 Dec 1993, GRANTED,
Pat. No. US 5753225
DT Utility
FS APPLICATION
LN.CNT 1837
INCL INCLM: 424/143.100
NCL NCLM: 424/130.100
NCLS: 424/138.100; 424/141.100; 424/143.100; 424/156.100; 530/387.100;
530/388.100; 530/388.220
IC [7]
ICM: A61K039-395

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 10 OF 19 USPATFULL on STN
AN 2002:168201 USPATFULL
TI Method of enhancing effect of a neurotrophin with analogues of
p75NTR367-379.
IN Riopelle, Richard J., Kingston, CANADA
Weaver, Donald F., Kingston, CANADA
Ross, Gregory M., Kingston, CANADA
Shamovsky, Igor L., Kingston, CANADA
PA Queen's University at Kingston, Kingston, CANADA (non-U.S. corporation)
PI US 6417159 B1 20020709
AI US 1997-839131 19970423 (8)
PRAI GB 1996-8335 19960423
DT Utility
FS GRANTED
LN.CNT 1814
INCL INCLM: 514/002.000
INCLS: 514/014.000; 514/015.000; 514/214.000; 514/365.000; 514/424.000;

514/570.000; 514/634.000; 514/648.000
 NCL NCLM: 514/002.000
 NCLS: 514/014.000; 514/015.000; 514/212.050; 514/365.000; 514/424.000;
 514/570.000; 514/634.000; 514/648.000
 IC [7]
 ICM: A61K038-00
 ICS: A61K038-10; A61K031-55; A61K031-426
 EXF 514/14; 514/2; 514/15; 514/214; 514/365; 514/424; 514/570; 514/634;
 514/648
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 11 OF 19 PCTFULL COPYRIGHT 2004 Univentio on STN
 AN 2002067858 PCTFULL ED 20020916 EW 200236
 TIEN NOVEL TREATMENT OF NEURODEGENERATIVE DISEASES BY ALTERING LEVELS OF TRKB
 ISOFORMS AND/OR TRKC ISOFORMS
 TIFR NOUVEAU TRAITEMENT DE MALADIES NEURO-DEGENERATIVES PAR MODIFICATION DES
 PROPORTIONS D'ISOFORMES TRKB ET/OU TRKC
 IN KRUEGER, Bruce, K, 4085 Fragile Sail Way, Ellicott City, MD 21042, US
 [US, US];
 KINGSBURY, Tami, J, 622 Walker Avenue, Baltimore, MD 21212, US [US, US];
 BAMBRICK, Linda, L, 1912 Sulgrave Avenue, Baltimore, MD 21209, US [US,
 US];
 DORSEY, Susan, G, 937 Jubal Way, Frederick, MD 21701, US [US, US]
 PA UNIVERSITY OF MARYLAND, BALTIMORE, 520 West Lombard Street, Baltimore,
 MD 21201, US [US, US], for all designates States except US;
 KRUEGER, Bruce, K, 4085 Fragile Sail Way, Ellicott City, MD 21042, US
 [US, US], for US only;
 KINGSBURY, Tami, J, 622 Walker Avenue, Baltimore, MD 21212, US [US, US],
 for US only;
 BAMBRICK, Linda, L, 1912 Sulgrave Avenue, Baltimore, MD 21209, US [US,
 US], for US only;
 DORSEY, Susan, G, 937 Jubal Way, Frederick, MD 21701, US [US, US], for
 US only
 AG MARKS, David, L., University of Maryland, Baltimore, Office of Research
 and Development, 515 West Lombard Street, 5th Floor, Baltimore, MD
 21201, US
 LAF English
 LA English
 DT Patent
 PI WO 2002067858 A2 20020906
 DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU
 CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN
 IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN
 MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM
 TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW
 RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
 RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
 RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
 RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
 AI WO 2002-US5151 A 20020222
 PRAI US 2001-60/270,553 20010222

L8 ANSWER 12 OF 19 USPATFULL on STN
 AN 2001:126004 USPATFULL
 TI Method for treating cancer using a tyrosine protein kinase inhibitor
 IN Barbacid, Mariano, Lawrenceville, NJ, United States
 PA Bristol-Myers Squibb Co., New York, NY, United States (U.S. corporation)
 PI US 6271242 B1 20010807
 AI US 1992-834065 19920210 (7)
 DT Utility
 FS GRANTED
 LN.CNT 744
 INCL INCLM: 514/320.000
 INCLS: 514/211.000

NCL NCLM: 514/320.000
IC [7]
ICM: A01N043-40
EXF 514/211; 514/211.08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 13 OF 19 PCTFULL COPYRIGHT 2004 Univentio on STN
AN 2000027426 PCTFULL ED 20020515
TIEN METHOD FOR ENHANCING PROLIFERATION OF INNER EAR HAIR CELLS USING LIGANDS
FOR HER2 AND/OR HER3 RECEPTORS
TIFR PROCEDE PERMETTANT D'ACCENTUER LA PROLIFERATION DES CELLULES DE POILS DE
L'OREILLE INTERNE A L'AIDE DE LIGANDS DESTINES AUX RECEPTEURS HER2 ET/OU
HER3
IN GAO, Wei-Qiang
PA GENENTECH, INC.;
GAO, Wei-Qiang
LA English
DT Patent
PI WO 2000027426 A1 20000518
DS W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK
DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP
KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT
RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU
ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD
RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL
PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
AI WO 1999-US25744 A 19991028
PRAI US 1998-60/107,522 19981107
ICM A61K039-00
ICS A61K039-395; A61K038-18; C07K014-475

L8 ANSWER 14 OF 19 PCTFULL COPYRIGHT 2004 Univentio on STN
AN 2000027379 PCTFULL ED 20020515
TIEN PHARMACEUTICAL COMPOSITIONS COMPRISING PORPHYRINS AND SOME NOVEL
PORPHYRIN DERIVATIVES
TIFR COMPOSITIONS PHARMACEUTIQUES CONTENANT DES PORPHYRINES ET DES DERIVES
NOUVEAUX DE LA PORPHYRINE
IN YAYON, Avner;
AVIEZER, David;
GROSS, Zeev
PA YEDA RESEARCH AND DEVELOPMENT CO. LTD.;
TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD.;
YAYON, Avner;
AVIEZER, David;
GROSS, Zeev
LA English
DT Patent
PI WO 2000027379 A2 20000518
DS W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK
DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP
KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL
PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN
YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ
MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC
NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
AI WO 1999-IL602 A 19991108
PRAI IL 1998-126953 19981108
ICM A61K031-00

L8 ANSWER 15 OF 19 USPATFULL on STN
AN 1998:54480 USPATFULL
TI Antibodies that mimic actions of neurotrophins
IN Clary, Douglas O., San Francisco, CA, United States
Weskamp, Gisela, New York, NY, United States

Austin, Leeann R., San Francisco, CA, United States
Reichardt, Louis F., San Francisco, CA, United States
PA The Regents of the University of California, Oakland, CA, United States
(U.S. corporation)
PI US 5753225 19980519
AI US 1993-162597 19931203 (8)
DT Utility
FS Granted
LN.CNT 1850
INCL INCLM: 424/130.100
INCLS: 424/141.100; 424/143.100; 424/156.100; 530/387.100; 530/388.100;
530/388.220
NCL NCLM: 424/130.100
NCLS: 424/141.100; 424/143.100; 424/156.100; 530/387.100; 530/388.100;
530/388.220
IC [6]
ICM: A61K039-395
ICS: C07K016-00
EXF 435/244; 424/130.1; 424/143.1; 530/388.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 16 OF 19 USPATFULL on STN
AN 97:68592 USPATFULL
TI Indolocarbazole derivatives to treat a pathological condition of the
prostate
IN Dionne, Craig A., Harleysville, PA, United States
Contreras, Patricia C., West Chester, PA, United States
Murakata, Chikara, Tokyo, Japan
PA Kyowa Hakko Kogyo Co., Ltd., Tokyo, Japan (non-U.S. corporation)
Cephalon, Inc., West Chester, PA, United States (U.S. corporation)
PI US 5654427 19970805
AI US 1995-463680 19950605 (8)
RLI Division of Ser. No. US 1994-250175, filed on 27 May 1994, now patented,
Pat. No. US 5516771 which is a continuation-in-part of Ser. No. US
1993-96622, filed on 22 Jul 1993, now abandoned which is a
continuation-in-part of Ser. No. US 1993-69178, filed on 28 May 1993,
now abandoned
DT Utility
FS Granted
LN.CNT 1974
INCL INCLM: 540/545.000
INCLS: 548/416.000
NCL NCLM: 540/545.000
NCLS: 548/416.000
IC [6]
ICM: C07D498-22
EXF 540/545
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 17 OF 19 USPATFULL on STN
AN 96:41210 USPATFULL
TI Use of indolocarbazole derivatives to treat a pathological condition of
the prostate
IN Dionne, Craig A., Harleysville, PA, United States
Contreras, Patricia C., West Chester, PA, United States
Murakata, Chikara, Tokyo, Japan
PA Cephalon, Inc., West Chester, PA, United States (U.S. corporation)
Kyowa Hakko Kogyo Co., Ltd., Tokyo, Japan (non-U.S. corporation)
PI US 5516771 19960514
AI US 1994-250175 19940527 (8)
RLI Continuation-in-part of Ser. No. US 1993-96622, filed on 22 Jul 1993,
now abandoned which is a continuation-in-part of Ser. No. US 1993-69178,
filed on 28 May 1993
DT Utility

FS Granted
LN.CNT 1997
INCL INCLM: 514/211.000
INCLS: 514/410.000; 540/543.000; 540/545.000; 548/416.000
NCL NCLM: 514/211.080
NCLS: 514/410.000; 540/543.000; 540/545.000; 548/416.000
IC [6]
ICM: A61K031-55
EXF 514/211; 540/543; 540/545
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 18 OF 19 PCTFULL COPYRIGHT 2004 Univentio on STN
AN 1995015180 PCTFULL ED 20020514
TIEN ANTIBODIES THAT MIMIC ACTIONS OF NEUROTROPHINS
TIFR ANTICORPS IMITANT LES EFFETS DES NEUROTROPHINES
IN CLARY, Douglas, O.;
WESKAMP, Gisela;
AUSTIN, Leeann;
REICHARDT, Louis, F.
PA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
LA English
DT Patent
PI WO 9515180 A1 19950608
DS W: AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU
JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW NL NO NZ PL
PT RO RU SD SE SI SK TJ TT UA UZ VN KE MW SD SZ AT BE CH
DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM
GA GN ML MR NE SN TD TG
AI WO 1994-US13708 A 19941201
PRAI US 1993-8/162,597 19931203
ICM A61K039-395
ICS C07K016:28; C12N001:38; G01N033:53

L8 ANSWER 19 OF 19 PCTFULL COPYRIGHT 2004 Univentio on STN
AN 1994027982 PCTFULL ED 20020513
TIEN USE OF INDOLOCARBAZOLE DERIVATIVES TO TREAT A PATHOLOGICAL CONDITION OF
THE PROSTATE
TIFR UTILISATION DE DERIVES DE L'INDOLOCARBOZOLE POUR TRAITER UNE AFFECTION
DE LA PROSTATE
IN DIONNE, Craig, A.;
CONTRERAS, Patricia, C.;
MURAKATA, Chikara
PA CEPHALON, INC.;
KYOWA HAKKO KOGYO CO., LTD.
LA English
DT Patent
PI WO 9427982 A1 19941208
DS W: AU CA FI HU JP KR LK NO NZ PL RO RU UA AT BE CH DE DK ES
FR GB GR IE IT LU MC NL PT SE
AI WO 1994-US6082 A 19940527
PRAI US 1993-8/069,178 19930528
US 1993-8/096,622 19930722

=> d 1,3,10,12,16 hit

L8 ANSWER 1 OF 19 USPATFULL on STN
SUMM [0006] Neurotrophins comprise a class of polypeptide neuron survival factors that not only support the survival of post-mitotic neurons (Lewin and Barde, Physiology of the neurotrophins; Ann. Rev. Neurosci. 19:289-317 (1996)), but also regulate other neuronal functions, including, among others, axon growth and synaptic plasticity (Black I B, Trophic regulation of synaptic plasticity; J. Neurobiol. 41:108-118 (1999); Lentz; et al., Neurotrophins support the development of diverse

sensory axon morphologies; J. Neurosci. 19:1038-1048 (1999); Lu and Chow, Neurotrophins and hippocampal synaptic transmission and plasticity; J. Neurosci. Res. 58:76-87 (1999); McAllister et al., Neurotrophins and synaptic plasticity, Ann. Rev. Neurosci. 22:295-318 (1999); Schinder and Poo, The neurotrophin hypothesis for synaptic plasticity, Trends Neurosci. 23:639-645 (2000); Thoenen, Neurotrophins and activity-dependent plasticity, Prog. Brain Res. 128:183-191 (2000)). The class of neurotrophins includes, but is not limited to, nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4/5 (NT-4/5). Neurotrophins bind to receptors and **activate** tyrosine receptor kinases (trks) (Barbacid, The Trk family of **neurotrophin receptors**, J. Neurobiol. 25:1386-1403 (1994); Bothwell, Functional interactions of neurotrophins and neurotrophin receptors, Ann. Rev. Neurosci. 18:223-253 (1995)). NGF primarily acts via TrkA; BDNF and NT-4/5 primarily via TrkB; and NT-3 primarily via TrkC. However the specificity of these interactions are not absolute. Binding of neurotrophins to trk dimers initiates trans auto-phosphorylation of specific tyrosine residues on the intracellular domain of the receptor (Segal and Greenberg, Intracellular signaling pathways activated by neurotrophic factors, Ann. Rev. Neurosci. 19:463-489 (1996); Kaplan and Miller, Neurotrophin signal transduction in the nervous system, Curr. Opin. Neurobiol. 10:381-391 (2000)). These phospho-tyrosine residues serve as docking sites for elements of intracellular signaling cascades that lead to the suppression of neuron death and other effects of the neurotrophins. TrkB and TrkC are also present as truncated forms which lack the intracellular kinase domain and are, therefore, incapable of normal phosphorylation (Klein et al., The trkB tyrosine protein kinase gene codes for a second neurogenic receptor that lacks the catalytic kinase domain, Cell 61:647-656 (1990); Middlemas et al., trkB, a neural receptor protein-tyrosine kinase: evidence for a full-length and two truncated receptors, Mol. Cell Biol. 11:143-153 (1991); Tsoulfas et al., The rat trkC locus encodes multiple neurogenic receptors that exhibit differential response to neurotrophin-3 in PC12 cells, Neuron 10:975-990 (1993)). The full-length and truncated trk isoforms are generated by alternative splicing of the primary trk RNA. While there is some evidence that activation of truncated trk receptors can elicit cellular responses independently of normal tyrosine phosphorylation (Baxter et al., Signal transduction mediated by the truncated trkB receptor isoforms, trkB.T1 and trkB.T2, J. Neurosci. 17:2683-2690 (1997); Hapner et al., Neural differentiation promoted by truncated trkC receptors in collaboration with p75(NTR), Dev. Biol. 201:90-100 (1998); Haapasalo et al., Expression of the naturally occurring truncated trkB neurotrophin receptor induces outgrowth of filopodia and processes in neuroblastoma cells, Oncogene 18:1285-1296 (1999)), truncated trk receptors are generally thought to inhibit trk-mediated neurotrophin signaling by interacting with full-length receptors to form inactive heterodimers (Eide et al., Neurotrophins and their receptors-current concepts and implications for neurological disease, Exp. Neurol. 121:200-214 (1996)). The expression of truncated trk receptors is developmentally regulated (Fryer et al., Developmental and mature expression of full-length and truncated trkB receptors in the rat forebrain, J. Comp. Neurol. 374:21-40 (1996)) and may represent a normal mechanism for modulating the cellular response to specific neurotrophins (Ninkina et al., Expression and function of TrkB variants in developing sensory neurons, EMBO J. 15:6385-6393 (1996)).

DETD [0111] If TrkB.T1 acts by a dominant negative mechanism to reduce TrkB signaling, there should be less BDNF-stimulated tyrosine phosphorylation of TrkB in Ts16 neurons. To test this prediction phosphorylation of TrkB was measured by western blot analysis using **antibodies** specific for **phosphotyrosine** in position Y490 in TrkB.FL. This **antibody** was raised to phospho-TrkA and it also recognizes the corresponding phosphorylated tyrosine in TrkB and TrkC. Because there is no detectable TrkA in mouse hippocampal neurons and any BDNF-stimulated

phospho-TrkC could be distinguished on the basis of molecular size on these gels, in mouse hippocampal neurons, the BDNF-induced increase in trk phosphorylation determined with this antibody is phospho-TrkB. Euploid and Ts16 neuron cultures were preincubated without B27 for 4 hours and then in the absence or presence of 100 ng/ml BDNF for 5 minutes. Cells were subjected to western blot analysis as described above using anti-phospho-Trk (P-TrkB) or TrkB(out) (TrkB).

L8 ANSWER 3 OF 19 USPATFULL on STN

SUMM Nerve growth factor (NGF) was characterized over 4 decades ago, and like the other neurotrophins subsequently discovered it is best known for its trophic role, including the prevention of programmed cell death in specific populations of neurons in the peripheral nervous system. This property can be accounted for by the activation of a tyrosine kinase receptor. NGF also regulates neuronal function, as illustrated by its role in pain and inflammation, and in synaptic plasticity. Numerous studies published in the last 10-15 years have shown that NGF, a polypeptide originally discovered in connection with its neurotrophic activity, also acts on cells of the immune system. Finally, NGF recently was shown (Frade and Barde, 1998) to **activate** the **neurotrophin receptor p75 (p75M)**, a receptor with no intrinsic catalytic activity and with similarities to members of the tumor necrosis factor receptor family. During normal development, the activation of p75NTR by NGF actually kills cells in the central nervous system (Frade and Barde, 1998). One remarkable property of NGF is then that it controls cell numbers in opposite ways in the developing nervous system, a result of its unique ability to activate two different receptor types. NGF has been found in various immune organs including the spleen, lymph nodes and thymus, and cells such as mast cells, eosinophils, and B and T cells (Aloe et al, 1997).

DRWD FIG. 14 is an immunoblot showing total FGFR-3 tyrosine phosphorylation induced by FGF-9. Phosphorylation level of FGFR-3 tyrosine kinase in the presence of P16 was demonstrated by immunoprecipitation of FGFR-3 with anti-FGFR-3 **antibodies** and immunoblotting with anti-**phosphotyrosine antibodies**.

DETD Human recombinant bFGF was from American Cyanamid (Pearl River, N.Y.); heparin-coated plates were from Carmeda (Sweden); FRAP was prepared as described (Ornitz et al, 1992); NIH 3T3 cells expressing signal peptide bFGF were generated as described (Yayon and Klagsbrun, 1990); anti-FGFR3 **antibody** and anti-**phosphotyrosine antibody** PY-20 were purchased from Santa Cruz Biotechnology (Santa Cruz, Calif.); anti-ERK 1,2 antibody was purchased from Sigma; DMEM was from Bet Haemek Biological Industries (Israel); compounds P1, P2, P3, P4, P5 were either synthesized or purchased from Aldrich (catalog Nos 32,349-7, 25,292-1, 25,288-3, 41,2066, 30,678-9, respectively); human recombinant VEGF was generated by H. Weich, Braunschweig (Germany); anti-AP antibodies were prepared as previously described (Ornitz et al, 1992).

DETD In order to measure the ability of the porphyrins to inhibit the receptor activation on an enzymatic level as well, FGFR-3 tyrosine phosphorylation was measured in the presence of P16, as described in Methods, section (viii). Immunoprecipitation of FGFR-3 with the anti-FGFR-3 **antibodies** and immunoblotting with anti-**phosphotyrosine antibodies** demonstrated that P16 reduced both the basal and, to a much greater extent, the FGF-9 induced phosphorylation of FGFR-3 (FIG. 14), indicating that P16 has a significant, direct and highly specific effect on FGFR-3 activity.

L8 ANSWER 10 OF 19 USPATFULL on STN

DRWD FIG. 7B illustrates the influence of peptide R3 on TrkA phosphorylation. PC12 cells were treated with R3 for 30 min or 24 h and suspended in HKR buffer at a concentration of 10.sup.7.multidot.ml.sup.-1. NGF (50 ng.multidot.ml.sup.-1) was added where indicated and samples incubated for 15 min at 37° C. Cells were subsequently harvested by

centrifugation and the pellets dissolved in lysis buffer and immunoprecipitated for TrkA as described. Immunoprecipitated proteins were separated using 7.5% polyacrylamide gels (Laemmli) and transblotted to PVDF membrane. The membrane was processed for anti-**phosphotyrosine** with HRP-conjugated **antibody** RC-20 as described by the manufacture's literature (Transduction Laboratories Ltd.).

- DETD Carter B. D., Kaltschmidt C., Kaltschmidt B., Offenhauser N., Bohm-Matthaei R., Baeuerle P. A. and Barde Y.-A. (1996) Selective **activation** of NFkB by nerve growth factor through the **neurotrophin receptor** p75. *Science* 272, 542-545.
- DETD Dombrowsky, R. T., Werner, M. H., Castellino, A. M., Chao, M. V. and Hannum, Y. A. (1994) **Activation** of the sphingomyelin cycle through the low-affinity **neurotrophin receptor**. *Science* 265, 1596-1599.
- L8 ANSWER 12 OF 19 USPATFULL on STN
- DRWD FIG. 4. K252a inhibits ligand-induced tyrosine phosphorylation of the trk family of receptors. (A) PC12 cells and quiescent (B) E25-42, (C) Z52-17 and (D) R4-31 cells were incubated for 18 hours in the absence (-) or presence (+) of 100 nM K252a. Cells were then incubated for an additional 5 minutes (PC12 cells) or 10 minutes (E25-42, Z52-17 and R4-31 cells) with (+) or without (-) 100 ng/ml of (A,B) NGF, (C) BDNF or (D) NT-3 prior to their lysis in P-TYR buffer. Cell lysates were immunoprecipitated with an anti-peptide antiserum elicited against the carboxy-terminus of gp140.sup.trk [(Martin-Zanca, D. et al., *Mol. Cell. Biol.* 9, 24-33, (1989))], which also recognizes the gp145.sup.trkB and gp145.sup.trkC receptors. The resulting immunoprecipitates were fractionated by 8% SDS-PAGE, transferred to nitrocellulose filters and blotted with anti-**phosphotyrosine** monoclonal **antibody** 4G10. Filters were incubated with [^{sup}.125 I]-protein A and exposed to Kodak X-Omat film at -70° C. with the help of intensifying screens for 12 to 48 hours. The migration of the gp140.sup.trk, gp145.sup.trkB and gp145.sup.trkC tyrosine protein kinases is indicated by arrows. It should be noted that the migration of gp140.sup.trk in PC12 and E25-42 cells varies slightly, most likely due to differential glycosylation. Co-electrophoresed molecular weight markers were those described in the legend to FIG. 2.
- DRWD FIG. 7. Dose-dependent inhibition of in vivo tyrosine phosphorylation of trk oncoproteins by K252a. NIH3T3 cell lines transformed by (A) a human coloncarcinoma trk oncogene (106-632 cells), (B) the trk5 oncogene (B38-941 cells), and (C) v-src (C74-321 cells) were incubated for 18 hours in the presence of the indicated concentrations of K252a prior to lysis in PTYR buffer. Cell lysates were immunoprecipitated with (A,B) anti-gp140.sup.trk antiserum or (C) anti-pp60.sup.v-src monoclonal antibody 327 and fractionated by 8% SDS-PAGE. Samples were transferred to nitrocellulose filters and blotted with (A,B) anti-**phosphotyrosine** monoclonal **antibody** 4G10 or (C) polyclonal **phosphotyrosine** antiserum. Filters were incubated with [^{sup}.125 I]-protein A and exposed to Kodak X-Omat film at -70° C. with the help of intensifying screens for 6 hours. The migration of p70.sup.trk, gp120.sup.trk5 and pp60.sup.v-src is indicated by arrows. Co-electrophoresed molecular weight markers are those described in the legend to FIG. 2.
- DETD K252a was obtained from Kamiya Biomedical Company (Thousand Oaks, Calif.), dissolved in DMSO and stored in the dark at -20° C. Murine EGF, acidic and basic FGFs, 2.5 S NGF and human AB PDGF were purchased from Upstate Biotechnology Inc. (New York). BDNF and NT-3 were purified to about 95% homogeneity from supernatants of Sf9 insect cells infected with recombinant baculoviruses pAcS27 (BDNF) and pAcS28 (NT-3) as previously described (Cordon-Cardo, C., et al. (1991). *Cell*, 66, 173-183). Antisera included a rabbit antiserum (43-4) raised against a peptide corresponding to the carboxyl terminus of the gp140.sup.trk receptor (Martin-Zanca, D., et al. (1989). *Mol. Cell. Biol.*, 9, 24-33),

a rabbit polyclonal antiserum (anti-PR 4, a gift of S. Courtneidge) against PDGF receptor (Kypta, R. M., et al. (1990). Cell, 62, 481-492), anti-human EGF receptor monoclonal antibody (Upstate Biotechnology Inc.), anti-pp60.sup.v-src monoclonal **antibody** 327 (Oncogene Sciences), anti-**phosphotyrosine** monoclonal **antibody** 4G10 (Upstate Biotechnology Inc.) and affinity purified rabbit anti-mouse immunoglobulins (Dako). A polyclonal phosphotyrosine antisera was prepared by immunization of rabbits with a poly-phosphotyrosine-glycine-alanine immunogen as described in Kamps, M. P. & Sefton, B. M. (1988). Oncogene, 2, 305-315.

DETD These results suggest that K242a blocks a specific component of the NGF-activated signal transduction pathway, most likely a protein kinase. Therefore, it was investigated whether K252a might block NGF-induced PC12 differentiation by inhibiting the tyrosine kinase activity of the NGF receptor, gp140.sup.trk. For this purpose, serum-starved PC12 cells were incubated with 100 ng/ml of NGF in the absence or presence of 100 nM K252a. Cell extracts were immunoprecipitated with antibodies elicited against the carboxy terminal domain of gp140.sup.trk, fractionated by SDS-PAGE and blotted with anti-**phosphotyrosine antibodies**. As shown in FIG. 2A, K252a completely abolished NGF-induced phosphorylation of gp140.sup.trk on tyrosine residues. Incubation of NIH3T3 cells with 100 ng/ml of PDGF in the presence of 100 nM K252a had no effect on the phosphorylation on tyrosine residues of the PDGF receptor (FIG. 2C). Similar results were obtained when F19-91 cells, a NIH3T3 cell line overexpressing the human EGF receptor, with 100 ng/ml of EGF, were stimulated (FIG. 2B). These observations indicate that K252a is an inhibitor of the gp140.sup.trk tyrosine kinase receptor.

DETD The gp140.sup.trk NGF receptor is a member of a small family of related tyrosine protein kinases which included gp145.sup.trkB, a product of the trkB gene (Klein, R., et al. (1989). EMBO J., 8, 3701-3709; Klein, R., et al. (1990). Cell, 61, 647-656; Middlemas, D. S., et al. (1991). Mol. Cell. Biol., 11, 143-153), which mediates the biological activity of BDNF and to a lesser extent of NT-3 (Glass, D. J., et al. (1991). Cell, 66, 405-413; Klein, R., et al. (1991). Cell, 66, 395-403; Soppet, D., et al. (1991). Cell, 65, 895-903; Squinto, S. P., et al. (1991). Cell 65, 885-893), and gp145.sup.trkC, a tyrosine protein kinase encoded by the trkC gene and a receptor specific for NT-3 (Lamballe, F., et al. (1991). Cell, 66, 967-979). It was investigated whether K252a was also an efficient inhibitor of the activation of these trk-related receptors by their cognate ligands. For this purpose, PC12 cells expressing gp140.sup.trk and NIH3T3 cell lines ectopically expressing gp140.sup.trk (E25-42 cells), gp145.sup.trkB (Z52-17 cells) and gp145.sup.trkC (RA-31 cells) were incubated with 100 ng/ml of NGF, BDNF and NT-3 respectively, in the absence or presence of 100 nM K252a. Cell extracts were immunoprecipitated with anti-gp140.sup.trk antibodies known to recognize each of the above receptors, fractionated by SDS-PAGE and blotted with antiphosphotyrosine antibodies. As shown in FIG. 4, 100 nM K252a completely abolished the phosphorylation on tyrosine residues of each of three ligand-**activated** receptors. Thus, K252a appears to be an inhibitor of the trk family of **neurotrophin receptors**.

L8 ANSWER 16 OF 19 USPATFULL on STN

SUMM By a "functional derivative of K-252a" is meant a K-252a derivative that inhibits the tyrosine kinase (TK) activity associated with a **neurotrophin receptor**, e.g., trkA, trkB or trkC. Preferably the **neurotrophin receptor** is trkA, and is **activated** when contacted by NGF. The TK activity of the trks in the presence of the K-252a derivative is preferably less than the TK activity of the trks in the absence of the K-252a derivative. The TK activity of the trks can be measured according to the methods disclosed herein.

DETD PC12 cells (ATCC #CRL1721) are rat pheochromocytoma cells that bear trkA and differentiate into sympathetic neurons when treated with NGF. These cells were grown in 100 mm dishes in DMEM media (GIBCO) containing 7.5% fetal bovine serum, 7.5% horse serum, 2 mM glutamine, 1 mM pyruvate. Cells were incubated at 37° C. in a humidified atmosphere of 10% CO.sub.2 and 90% air. Subconfluent cell cultures were incubated in medium without serum for one hour, incubated for one hour with a K-252a derivative compound at a concentration of 100 nM or 500 nM, and then stimulated for 5 minutes with NGF at a concentration of 50 ng/ml. The cells in each culture were disrupted and cell lysates were prepared by standard techniques known to those skilled in the art. Each lysate was incubated with anti-trk antibody whereby immune complexes were formed. Polyclonal anti-trkA, B, and C antibodies were prepared against the C-terminal 16 amino acids of trk (Kaplan et al. 1991 supra). The immune complexes were collected on Protein A-Sepharose beads, separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE), and transferred to polyvinylidene difluoride (PVDF) membranes (Millipore Corp., Bedford, Mass.), using techniques well known to those skilled in the art. The membranes were incubated with anti-**phosphotyrosine antibody**, which binds to the tyrosine phosphorylated trks, but not to the un-phosphorylated form of trks. Proteins bound to anti-**phosphotyrosine antibody** were visualized with enhanced chemiluminescence (ECL, Amersham), and are shown as dark "spots" in FIG. 1.

=>